ACA
ABBV icon

Aptus Capital Advisors’s AbbVie ABBV Stock Holding History

Aptus Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-28,800
Closed -$2.55M – 407
2019
Q4 		$2.55M Buy
28,800
+800
+3% +$66.4K 0.18% 114
2019
Q3 		$2.12M Buy
+28,000
New +$1.92M 0.12% 117

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aptus Capital Advisors's ABBV Position: Q1 2026 in Review

Aptus Capital Advisors reduced its AbbVie (ABBV) stake by 2% in Q1 2026, selling an estimated $618K and leaving 134,719 shares worth $29.3M. The position accounts for 0.23% of the portfolio, ranked #87.

Aptus Capital Advisors first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $31.4M in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Aptus Capital Advisors held 134,719 shares of AbbVie worth $29.3M as of Q1 2026.
  • Aptus Capital Advisors sold 2,786 AbbVie shares in Q1 2026, an estimated $618K.
  • AbbVie made up 0.23% of Aptus Capital Advisors's portfolio in Q1 2026, its #87 holding.
  • Aptus Capital Advisors first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • Aptus Capital Advisors's AbbVie position peaked at $31.4M in Q4 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.